Progress in ovarian cancer diagnostics;Postepy w diagnostyce raka jajnika

Przeglad Menopauzalny

Volumn 5, Issue 1, 2006, Pages 12-16

  Nowak Markwitz, Ewa ^a   Spaczyński, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biomarkers; Genomics; Ovarian cancer; Proteomics; Screening

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EARLY CANCER; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; MASS SPECTROMETRY; OVARY CANCER; PROCESS DEVELOPMENT; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYMPTOMATOLOGY; TISSUE TYPES;

EID: 33644900981     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Tiwari R, Murray T. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8-29.
2. Cannistra S. Cancer of the ovary. N Engl J Med 2004; 351 (24): 2519-29.
3. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21 (10 Suppl): 200-5.
4. Wilson J, Jungner G. The WHO principles and practice of screening for disease. Geneva: World Health Organization; 1968.
5. Menon U, Jacobs I. Ovarian cancer screening in the general population. Ultrasound Obstet Gynecol 2000; 15 (5): 350-53.
6. Jacobs I, Skates S, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 1999; 353 (9160): 1207-10.
7. Kerbarat P, Lhomme C, Fervers B, et al. Ovarian cancer. Br J Cancer 2001; 84:18-23.
8. Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 evaluation in malignant and nonmalignant disease. Gynecol Oncol 2002; 85 (1): 175-78.
9. Skates SJ, Menon U, MacDonald N, et al. Detection in postmenopausal women. J Clin Oncol 2003; 21: 206-10.
10. Cohen L, Escobar P, Scharm C. et al. Three-dimensional power ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001; 82 (1):40-48.
11. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343 (2): 78-85.
12. Grzybowska E, Zientek H, Jasińska A, et al. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mut 2000; 16 (6): 482-90.
13. Shih I, Kurman R. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164 (5): 1511-8.
14. Schutter EM, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002; 187 (2): 385-92.
15. Woolas R, Conaway M, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59 (1): 111-6.
16. van Hafften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA125 as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001; 92 (11): 2837-44.
17. Spentzos D, Levine D, Ramoni M, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004, 22: 4648-58.
18. Wong K, Cheng R, Mok S. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001; 30: 670-75.
19. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian cancer. Cancer Res 2003; 63 (13): 3695-3700.
20. Mok S, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93 (19): 1458-64.
21. Kim J, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287 (13): 1671-9.
22. Diamandis E, Yousef G. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002; 48 (8): 1198-1205.
23. Luo L, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel blomarker for ovarian cancer. Cancer Res 2003; 63 (4): 807-11.
24. Rosenblatt K, Bryant-Greenwood P, Killian K, et al. Serum proteomics in cancer diagnosis and management. Ann Rev Med 2004; 55: 97-112.
25. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 (9306): 572-7.
26. Kozak K, Amneus M, Pusey S, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange Protein Chips: potential use in diagnosis and prognosis. Proc Natl Acak Sci 2003;100 (21): 12343-48.
27. Yones M, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2 (1): 76-84.
28. Ardekani A, Liotta L, Petricoin EF 3 rd. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002; 2 (4): 312-20.
29. Ye B, Cramer D, Skates S, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9 (8): 2904-11.
30. Bast Jr R, Badgwell D, Lu z, et al. New tumor markers: CA 125 and beyond. Int J Gynecol Cancer 2005; 15: 273-81.
31. Boyce E, Kohn E. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 2005; 15 Suppl 3: 266-73.
32. Carr K, Rosenblatt K, Petricoin E, et al. Genomic and proteomic approaches to study human cancer: prospects for true patient-tailored therapy. Hum Genomics 2003; 1 (2): 32-38.